

AB



W₂ is not present or is selected from the group consisting of C=O, SO₂, SO, and C(O)NH;

R^1 and R^3 are each independently selected from the group consisting of: H; and cyclic or acyclic straight- or branched-chain, saturated or unsaturated C_1 - C_{14} alkyl groups, which are unsubstituted or substituted with one or more substituents selected from the group consisting of hydroxy, lower alkoxy, alkylthio, aryloxy, and arylthio groups, where the aryl-bearing groups are each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, lower alkyloxy, alkylthio, lower alkyl, trifluoromethoxy, trifluoroethoxy, and trifluoromethyl groups, and the alkyl-bearing groups are unsubstituted or substituted with one or more substituents selected from the group consisting of cyclic structures having a ring size of from 3 to 10 atoms and aryl and heteroaryl groups unsubstituted or substituted with one or more substituents selected from the group consisting of lower alkyl, alkoxy, amino, lower alkylamino, lower acylamino, halogen, trifluoromethyl and trifluoromethoxy groups;

- 3 -

A3
cont

alkyl groups, which are unsubstituted or substituted with one or more substituents selected from the group consisting of non-aromatic cyclic structures having from 3 to 14 ring atoms, aromatic and heteroaromatic structures, and heterocyclic rings having from 4 to 12 ring atoms, the aromatic and heteroaromatic structures being unsubstituted or substituted with one or more substituents selected from the group consisting of lower alkyl, alkoxy, amino, lower alkylamino, lower acylamido, halogen, perfluoroalkyl, perfluoro-lower alkoxy, and aryl and heteroaryl groups, the aryl and heteroaryl groups being unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, lower alkoxy, alkylthio, lower alkyl, trifluoromethoxy and trifluoromethyl groups; and aryl and heteroaryl groups unsubstituted or substituted with one more substituents selected from the group consisting of halogen, lower alkoxy, alkylthio, lower alkyl, trifluoromethoxy, and trifluoromethyl groups;

R^6 is selected from the group consisting of H, $R^{6'}$, $R^{6'}-NH$, and $R^{6'}-N$ -lower alkyl, where $R^{6'}$ is selected from the group consisting of: cyclic or acyclic straight- or branched-chain, saturated or unsaturated C_1-C_{14} alkyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; condensed aryl-lower alkyl; condensed heteroaryl-lower alkyl; bis-aryl-lower alkyl; bis-heteroaryl-lower alkyl; heteroaryl-lower alkyl-aryl; and partially or fully saturated derivatives thereof;

R^{10} is selected from the group consisting of: H; and cyclic or acyclic straight- or branched-chain, saturated or unsaturated C_1-C_{12} alkyl groups; aryl groups unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, alkoxy, aminoalkyl, di-(lower alkyl)-amino-lower alkyl, and hydroxy; arylalkyl; aryloxyalkyl; 2-tetrahydrofuryl; 3-tetrahydrofuryl; terminal hydroxyalkyl; and amidoalkyl;


or R⁹ and R¹⁰ together with the nitrogen to which they are bonded form a 3- to 10-membered ring;

Q is selected from: $(-\text{CH}_2-)_z$, where z is an integer of from 1 to 12, unsubstituted or substituted with one or more substituents selected from the group consisting of lower alkyl, aryl, and heteroaryl, and where when z is >1, one or more $-\text{CH}_2-$ each is optionally replaced by an atom selected from O, S, and N, with N being optionally substituted with lower alkyl, aryl, or heteroarylalkyl; $-(\text{CH}_2)_m-(\text{CH}_2)_x-$, where l and m are each independently an integer of from 0 to 5 and x is an integer from 3 to 12, where $(\text{CH}_2)_x$ is a 3- to 12-membered saturated carbocyclic or heterocyclic ring unsubstituted or substituted with one or more substituents selected from the group consisting of lower alkyl, cycloalkyl, aryl, and heteroaryl, where when the ring is heterocyclic, one or more of the ring $-\text{CH}_2-$ units is replaced by a heteroatom selected from O, S, Se, and N, with N being unsubstituted or substituted with lower alkyl, aryl, or heteroaryl; and $-(\text{CH}_2)_m-(\text{CH}=\text{CH})_y-$, where l and m are each independently an integer of from 0 to 5 and y is 2 or 3, and where $(\text{CH}=\text{CH})_y$ is a 4- to 6-membered aromatic carbocyclic or heterocyclic ring unsubstituted or substituted with one or more substituents selected from the group consisting of saturated or unsaturated, straight- or branched-chain alkyl groups, lower alkoxy groups, and halogens, where when the ring is heterocyclic, one or more of the ring $-\text{CH}-$ or $-\text{CH}=\text{CH}-$ units is replaced by a heteroatom selected from O, S, Se, and N, with N being optionally substituted with lower alkyl, aryl, or heteroaryl; and

X₃ is selected from the group consisting of H, lower alkyl, aryl, lower alkoxy, hydroxy, and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.


14. A compound according to claim 13 of formula:



wherein the variables are as previously defined,


or a pharmaceutically acceptable salt thereof.

15. A compound or a pharmaceutically acceptable salt thereof according to claim 14, wherein Q is selected from the group consisting of:




wherein l and m are each independently 0 or 1.

16. A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein Q is selected from the group consisting of:




17. A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein the compound is of the formula:




wherein the variables are as previously defined.

18. A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein R⁶ is selected from the group consisting of aryl, heteroaryl, aryl-lower alkyl, heteroaryl-lower alkyl, condensed aryl-lower alkyl, condensed heteroaryl-lower alkyl, bis-aryl-lower alkyl, bis-heteroaryl-lower alkyl, heteroaryl-lower alkyl-aryl, and partially or fully saturated derivatives thereof.


19. A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein R⁶ is selected from the group consisting of:







20. A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein R^{10} is selected from the group consisting of: cyclic or acyclic straight- or branched-chain, saturated or unsaturated C_1 - C_{12} alkyl; aryl unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, alkoxy, aminoalkyl, di-(lower alkyl)-amino-lower alkyl, and hydroxy groups; arylalkyl; aryloxyalkyl; 2-tetrahydrofuryl; 3-tetrahydrofuryl; terminal hydroxyalkyl; and amidoalkyl.

21. A compound or a pharmaceutically acceptable salt thereof according to claim 13, wherein R^{10} is selected from the group consisting of:





22. A compound according to claim 13 of the formula:




wherein the variables are as previously defined,
 or a pharmaceutically acceptable salt thereof.

23. A compound or pharmaceutically acceptable salt according to claim 22, wherein R^1 , R^3 , R^5 , R^7 , and R^{10} are each H.

24. A compound or a pharmaceutically acceptable salt thereof according to claim 14, wherein R^1 , R^3 , R^5 , R^7 , and R^9 are each H; R^{11} (where present) is H or methyl; and A^1 is NH.

25. A compound according to claim 13 having the formula:



or a pharmaceutically acceptable salt thereof.--

REMARKS

Claims 11-25 are pending.

By the above amendment, apparent clerical informalities in the specification have been corrected. Claims 11 and 12 have been amended and new claims 13-25 added to more clearly point out the elected subject matter.

The new claims are supported by, *inter alia*, the original claims. Additionally, support for new independent claim 13 includes the formulae and definitions on pages 4-6 of the specification. New dependent claim 14 is supported by, e.g., the first two formulae depicted on page 8 of the specification. Claim 15 draws support from, e.g., formulae Ia - Ie on pages 8-10 of